Deals this week: Deciphera Pharmaceuticals, Tricida, ENYO Pharma

8th June 2018 (Last Updated June 8th, 2018 00:00)

Deciphera Pharmaceuticals has raised $97.16m through an underwritten public offering of 3.75 million shares of its common stock.

Deciphera Pharmaceuticals has raised $97.16m through an underwritten public offering of 3.75 million shares of its common stock.

The underwriters will receive a 30-day option to buy an additional 562,500 shares.

Based in the US, Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel drugs.

The company plans to use the funds towards clinical trials, working capital and other general corporate purposes.

Tricida has filed a preliminary prospectus with the US Securities and Exchange Commission to raise $150m through an initial public offering of shares of its common stock.

The company plans to use the funds to support its filing for TRC101 to the FDA, towards manufacturing activities, and to conduct safety trials. Part of the funds will also be used for working capital and other general corporate purposes.

Based in the US, Tricida is a biopharmaceutical company that develops therapies for conditions associated with chronic kidney disease (CKD).

ENYO Pharma has raised €40m ($46.63m) through a series B financing round participated by new and existing investors.

The company plans to use the funds to finance the Phase II clinical trial of its EYP001 asset in both chronic hepatitis B (HBV) and non-alcoholic steatohepatitis (NASH).

"ENYO Pharma has raised €40m ($46.63m) through a series B financing round participated by new and existing investors."

Based in France, ENYO Pharma is a clinical-stage biotechnology company focused on drug discovery and development.

Catabasis Pharmaceuticals has filed a registration prospectus with the US Securities and Exchange Commission to raise $30m through a public offering of its common stock.

Each unit will include one share of the company’s common stock and a warrant, which will entitle the holder to buy one share of common stock. Based in the US, Catabasis is a clinical-stage biopharmaceutical company that provides orally administered pharmaceutical products.

The funds are intended to be used towards the company’s proposed Phase III clinical trial of edasalonexent, an investigational drug being developed as a potential treatment for Duchenne muscular dystrophy (DMD).

Translate Bio has filed a preliminary prospectus with the US Securities and Exchange Commission to raise $115m through an initial public offering of shares of its common stock.

The company plans to use the funds towards the development of MRT5005, a clinical-stage mRNA product candidate designed to address the primary cause of cystic fibrosis (CF).

Additionally, the funds will be used towards working capital and other general corporate purposes.

Based in the US, Translate Bio specialises in the discovery and development of therapeutics that activate ribonucleic acid (RNA).